Klein CE

No ORCID on file · 4 papers in corpus
2021
Pharmacokinetic and Pharmacodynamic Profiles of Ethinylestradiol/Norgestimate Combination or Norethindrone upon Coadministration with Elagolix 150 mg Once Daily in Healthy Premenopausal Women.
Clinical pharmacokinetics ·doi:10.1007/s40262-021-00989-0

BackgroundTwo pharmacokinetic/pharmacodynamic studies were conducted to evaluate the potential drug-drug interaction between elagolix, an oral gonadotropin-releasing hormone receptor antagonist, and an oral contraceptive (ethinylestradiol […

article 2019
Elagolix Suppresses Ovulation in a Dose-Dependent Manner: Results From a 3-Month, Randomized Study in Ovulatory Women
The Journal of clinical endocrinology and metabolism ·doi:10.1210/clinem/dgz086

CONTEXT: Elagolix is an oral gonadotropin-releasing hormone (GnRH) antagonist recently approved for the treatment of endometriosis-associated pain and being developed for heavy menstrual bleeding associated with uterine fibroids. OBJECTIVE:…

article 2018
Elagolix Pharmacokinetic Profiles in Women With Renal or Hepatic Impairment
Clinical pharmacology in drug development ·doi:10.1002/cpdd.640

The aim of these studies was to assess the safety and pharmacokinetics of elagolix, an oral nonpeptide gonadotropin-releasing hormone antagonist following oral administration in women with renal or hepatic impairment. Two phase 1 studies we…

article 2018
Population Pharmacokinetics of Elagolix in Healthy Women and Women with Endometriosis
Clinical pharmacokinetics ·doi:10.1007/s40262-018-0629-6

IntroductionElagolix is a novel, orally active, non-peptide, competitive gonadotropin-releasing hormone (GnRH) receptor antagonist in development for the management of endometriosis with associated pain and heavy menstrual bleeding due to u…